AD Check認知測™
Methods for the Effective and Accurate Detection of Early-Stage Cognitive Impairment
Phosphorylated-Tau217 (p-Tau217) Alzheimer’s Disease Blood Biomarker Test
- Breakthrough Device Designation granted by US FDA
- High Accuracy, Specificity, and Sensitivity
- Simple Blood Test, Non-invasive
- Test by Local Accredited Laboratory
AD Check認知測™ uses a breakthrough medical technology that has been clinically validated and recognized by the U.S. Food and Drug Administration (FDA). It precisely detects the p-Tau217 protein level, providing an accurate assessment of Alzheimer’s disease (AD) risk. This test serves as a reference for early screening and allows for regular monitoring of risk changes as individuals age.
陰性
Negative
臨界區間
Intermediate
陽性
Positive
AD Check認知測™ Use of Technology
Simoa, Single Molecule Array - Received
Breakthrough Medical Device Designation granted by U.S. FDA
Simoa is an ultra-sensitive biomarker detection method that can detect extremely low concentrations of p-Tau217 protein in plasma. This technology detects p-Tau217 with high sensitivity and specificity.
Accuracy
Up to 96%
Sensitivity
~98.2%
Specificity
~98.6%
Extensive medical literatures and clinical studies show:
p-Tau217 effectively detects Alzheimer’s Disease (AD)
What is Tau Protein?
Tau Protein is a type of protein found in nerve cells. When it becomes excessively phosphorylated, it loses its normal function and eventually forms fibrous neurofibrillary tangles. These aggregates can harm the health and function of neurons, leading to the development of Alzheimer’s Disease (AD).
Currently, phosphorylated Tau protein (p-Tau) has been clinically validated as a specific plasma biomarker that reflects the pathological features of AD. In patients with AD, p-Tau levels significantly increase. This increase occurs concurrently with the accumulation of extracellular beta-amyloid (Aβ) plaques, which is the hallmark of the AD.
What is p-Tau217 protein?
Among all Tau blood biomarkers, p-Tau217 performs exceptionally well in distinguishing Alzheimer’s disease(AD) from other neurodegenerative disease and is effective in detecting patients with mild cognitive impairment (MCI).
Compared to traditional testing:
Research shows that the AD Check認知測™ is consistent with the results of traditional positron emission tomography (PET) scans for amyloid-beta (PET-Aβ) and tau (PET-Tau), as well as cerebrospinal fluid (CSF) biomarkers (CSF Aβ42/40 and CSF p-tau181), (AUC 0.92-0.97).
Why take the AD Check認知測™?
Currently, neither pharmacological nor non-pharmacological treatments can reverse the damage caused by Alzheimer’s disease; they can only prevent or delay its onset through early-stage intervention.
AD Check認知測™ is effective in identifying risks at an early stage, research indicates that Mild Cognitive Impairment (MCI) stage has much better opportunity to slow down and improve condition.
Alzheimer’s Disease (AD) accounts for approximately 50-75%
AD Check認知測™ aids in the prevention or delay of disease progression.
Cognitive Impairment is divided into three stages.
Which stage is the most effective for treatment?
1. Normal Aging
Thinking and response times slow down
(MCI-AD)
2. Mild Cognitive Impairment
Memory begins to decline
(AD)
3.Late-Stage Alzheimer's Disease
Significant impact on daily living
Mild Cognitive Impairment (MCI-AD)
A Critical Stage for Delay AD
Once the condition progresses to Alzheimer’s disease, it deteriorates rapidly! Early detection of Alzheimer’s disease risk through timely screening allows for the delay of disease onset before further decline in cognitive abilities.
Latest
Early Alzheimer's Disease detection technology
AD Check認知測™
Patients with Mild Cognitive Impairment (MCI) are at high risk of developing Cognitive Impairment.
Approximately 10%-15% of patients
with Mild Cognitive Impairment (MCI) will progress to Cognitive Impairment each year.
~15%
Progression to Cognitive Impairment
The risk of MCI patientsprogressing to Cognitive Impairment
is up to 10 times higher than that of the general elderly population.
MCI patients are at
10 times higher risk.
AD Check認知測™ blood test for Alzheimer's Disease
Suitable Candidates for Testing
Aged 40 or above
Family History of AD
High-risk Factors of AD
（ Hypertension, high blood sugar, high cholesterol, history of stroke, or previous brain injuries ）
Sign of Cognitive Decline is Observed
APOE4 Gene Carriers
Depression/Living with High Stress
Smoking or Heavy Drinking
Test Procedures
1. Make an appointment for a blood test
2.Blood taking at appointed location
3.Test by local accredited medical laboratory
4.Report ready in 5-10 working days
AD Check™Blood Draw Points
Central
Room 601, 6/F, China Insurance Group Bldg., 141 Des Voeux Road, Central, Hong Kong
Room 618, 6/F., Central Building, 1-3 Pedder Street, Central, Hong Kong
Room 705, Melbourne Plaza, 33 Queens Road, Central, Hong Kong
Kornhill
Room 505, Office Tower, Kornhill Plaza, Quarry Bay, Hong Kong
Causeway Bay
- Unit 1902A, 19th Floor, East Point Centre, 555 Hennessy Road, Hong Kong
(Clearbridge Medical Center)
Mong Kok
Room 911, Phase 1 Argyle Centre, Mong Kok, Kowloon
Tsim Sha Tsui
Rm 08-09, 10/F, Mira Place Tower A, 132 Nathan Road, Tsim Sha Tsui, Hong Kong
(Life Young Health)
Tsuen Wan
Room 733, 7/F, 64-98 Sai Lau Kok Road, Nan Fung Centre, Y=Tsuen Wan, N.T.
Call or WhatsApp: : 6720 6859 / 9711 9922
